Nevro Corp. (NYSE:NVRO) Shares Sold by Nebula Research & Development LLC

Nebula Research & Development LLC cut its stake in shares of Nevro Corp. (NYSE:NVRO) by 13.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 43,666 shares of the medical equipment provider’s stock after selling 6,934 shares during the quarter. Nebula Research & Development LLC owned approximately 0.12% of Nevro worth $162,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in NVRO. Price T Rowe Associates Inc. MD grew its holdings in Nevro by 38.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 139,240 shares of the medical equipment provider’s stock worth $518,000 after acquiring an additional 38,869 shares in the last quarter. MYDA Advisors LLC purchased a new position in Nevro in the fourth quarter valued at $432,000. Canada Pension Plan Investment Board raised its stake in Nevro by 207.2% in the fourth quarter. Canada Pension Plan Investment Board now owns 25,500 shares of the medical equipment provider’s stock valued at $95,000 after buying an additional 17,200 shares in the last quarter. Barclays PLC lifted its holdings in Nevro by 12.9% during the 4th quarter. Barclays PLC now owns 69,416 shares of the medical equipment provider’s stock worth $258,000 after buying an additional 7,920 shares during the last quarter. Finally, Townsquare Capital LLC acquired a new position in shares of Nevro during the 4th quarter worth about $84,000. 95.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on NVRO. Canaccord Genuity Group upped their price target on Nevro from $4.00 to $5.85 and gave the company a “hold” rating in a report on Friday, February 7th. StockNews.com assumed coverage on shares of Nevro in a report on Thursday. They issued a “hold” rating for the company. Piper Sandler upgraded shares of Nevro from a “neutral” rating to an “overweight” rating and cut their price target for the stock from $6.00 to $5.85 in a research note on Friday, February 7th. Finally, Jefferies Financial Group upgraded shares of Nevro from an “underperform” rating to a “hold” rating and upped their price objective for the company from $4.50 to $5.85 in a research note on Monday, February 10th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $5.36.

Nevro Trading Up 0.1 %

Shares of NVRO stock opened at $5.85 on Friday. Nevro Corp. has a twelve month low of $3.17 and a twelve month high of $11.79. The company has a current ratio of 5.02, a quick ratio of 3.76 and a debt-to-equity ratio of 0.67. The business’s 50 day moving average is $5.82 and its two-hundred day moving average is $5.08. The company has a market capitalization of $224.32 million, a P/E ratio of -3.09 and a beta of 0.81.

Nevro (NYSE:NVRO) last announced its quarterly earnings data on Tuesday, March 4th. The medical equipment provider reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.15. The company had revenue of $105.55 million for the quarter, compared to analysts’ expectations of $102.61 million. Nevro had a negative net margin of 16.54% and a negative return on equity of 23.52%. Equities analysts forecast that Nevro Corp. will post -2.44 EPS for the current year.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.